Opthalmic Drugs Market is estimated to be US$ 132.06 billion by 2030 with a CAGR of 4.30% during the forecast period.

 



Opthalmic Drugs Market is estimated to be US$ 132.06 billion by 2030 with a CAGR of 4.30% during the forecast period. Ophthalmic drug is that the administration of a drug to the eyes, most typically as an eye fixed drop formulation. Topical formulations are wont to combat a mess of diseased states of the attention. These states may include bacterial infections, eye injury, glaucoma, and dry eye. However, there are many challenges related to topical delivery of medicine to the cornea of the attention. The most important factor that has got to be taken under consideration when designing any sort of drug delivery device, and specifically ocular devices, is that the release rate of a drug.

The report " Global Opthalmic Drugs Market, By Disease Indication (Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders (Wet Age-related Macular, Degeneration, Dry Age-related Macular Degeneration, Diabetic Retinopathy, and Others), By Therapeutic Class (Anti-inflammatory Drugs (Nonsteroidal Anti-inflammatory Drugs and Steroids), Anti-infective Drugs (Anti-fungal Drugs, Anti-bacterial Drugs, and Others), Anti-glaucoma Drugs (Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, and Others), Anti-allergy Drugs, Anti-VEGF Agents, and Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Independent Pharmacies and Drug Stores), and By Region (North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa) - Trends, Analysis, and Forecast till 2030”

Key Highlights:

·         In 2021, Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), announced its launch of the first available generic version of AZOPT® (brinzolamide ophthalmic suspension) 1%, approved by the US Food and Drug Administration to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma. Brinzolamide ophthalmic suspension 1% works by decreasing the amount of fluid within the eye.

·         IN 2019, Sun Pharmaceutical Industries Ltd. announced that one of its wholly-owned subsidiaries has commercialized CEQUA (cyclosporine ophthalmic solution) 0.09% in the U.S. CEQUA, which offers the highest concentration of cyclosporine for ophthalmic use approved by the U.S. Food and Drug Administration (FDA)

Analyst View:

Increasing incidence and prevalence of eye related disorders like presbyopia, degeneration, and diabetic retinopathy among the aging population. With the introduction of ophthalmic devices equipped with sophisticated technologies, people are increasingly choosing ophthalmic surgeries to correct their eye related disorders. Lack of insurance amongst population especially within the developing countries or lack of insurance covering all kinds of IOLs or contact in developed countries may be a significant challenge faced by the ophthalmology industry.

Before purchasing this report, request a sample or make an inquiry by clicking the following link:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/2230

 

Key Market Insights from the report:

The Global Opthalmic Drugs Market is estimated to be US$ 132.06 billion by 2030 with a CAGR of 4.30% during the forecast period.  The global opthalmic drugs market report segments the market on the basis of disease indication, therapeutic class, distribution channel, and region.

·         On the basis of Disease Indication, the global opthalmic drugs market is segmented into Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders (Wet Age-related Macular, Degeneration, Dry Age-related Macular Degeneration, Diabetic Retinopathy, and Others).

·         On the basis of Therapeutic Class, the target market is segmented into Anti-inflammatory Drugs (Nonsteroidal Anti-inflammatory Drugs and Steroids), Anti-infective Drugs (Anti-fungal Drugs, Anti-bacterial Drugs, and Others), Anti-glaucoma Drugs (Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, and Others), Anti-allergy Drugs, Anti-VEGF Agents, and Others).

·         On the basis of Distribution Channel, the target market divided into Hospital Pharmacies, Online Pharmacies, and Independent Pharmacies and Drug Stores.

·         Based on region the global orphan drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The global market in North America region is seen to have a matured growth since this market correlates with the increasing growth rate of eye disease. In North America region is the dominating region due to the U.S. is the largest share of market holder of the ophthalmic drugs. In U.S., FDA gives approval to the specific indication, tax credits for drugs.

Competitive Landscape:

Key players in the global opthalmic drugs market includes, Santen Pharmaceutical Co., Ltd., Bausch & Lomb Inc. (Valeant Pharmaceuticals International, Inc.), Shire Plc, Alcon (Novartis AG), Genentech, Inc., Allergan, Plc, Sun Pharmaceutical Industries Limited, Actavis Generics (Teva Pharmaceutical Industries Ltd.), Regeneron Pharmaceuticals, Inc., and Pfizer Inc.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

To know more

Contact Us:

Sales

Prophecy Market Insights

  1 860 531 2701

Email- sales@prophecymarketinsights.com

 

Comments

Post a Comment

Popular posts from this blog

Patient Portal Market is estimated to be US$ 7862.01 billion by 2030 with a CAGR of 11.50% during the forecast period

Image
  Patient Portal Market  accounted for US$ 2643.21 million in 2020 and is estimated to be US$ 7862.01 million by 2030 and is anticipated to register a CAGR of 11.50%. The patients can share and view their health information and communicate remotely. These characteristics enables patients to look into various data points, such as diagnostic test results, medical history, and prescription information. Patient portal is one of the many tools that allow the healthcare payers and providers to arrive at outcomes, which are patient-centric. Rapid technological advancements in the digital space are rising the engagement level of patients in the entire healthcare ecosystem. Data points collected on a per-patient basis through patient portal can be used for performing pin-point diagnosis, designing better clinical trials, and helping in the elimination of administration of redundant therapies and drugs to individual patients. The report   "   Global Patient Portal Market, By P...
Read more

Knee Replacement Market is estimated to be 14.2 billion by 2029 with a CAGR of 4.3% during the forecasted period.

Image
  knee replacement market  accounted for 9.7 billion in 2020 and is estimated to be US$ 14.2 billion by 2029 and is anticipated to register a CAGR of 4.3%. The report " Global Knee Replacement Market, By Product ( Total Knee Replacement, Partial Knee Replacement, Kneecap Replacement, and Complex (or revision) Knee Replacement),  By End Users ( Hospitals, Orthopedic Centers, and Other ),  and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029” . Key Highlights: In March 2018, Smith and Nephew announced commercial release of bi-cruciate retaining Journey II XR total knee arthroplasty across the U.S. and Japan. The product launch was aimed at capturing large customer base with innovative product offering. In October 2018, Zimmer Biomet Holdings announced to collaborate with Apple to facilitate patient and surgeon connection during the knee and hip replacement procedures. Th...
Read more

Nuclear Medicine Market is estimated to be US$ 6.49 billion by 2030 with a CAGR of 4.30% during the forecast period

Image
  The Nuclear Medicine Market accounted for US$ 4.26 billion and is estimated to be US$ 6.49 billion by 2030 with a CAGR of 4.30% during the forecast period. Nuclear medicine may be a medicine involving the appliance of radioactive substances within the diagnosis and treatment of disease. Medicine imaging, during a sense, is "radiology done inside out" or "endoradiology" because it records radiation emitting from within the body instead of radiation that's generated by external sources like X-rays. Additionally, medicine scans differ from radiology, because the emphasis isn't on imaging anatomy, but on the function. For such reason, it's called a physiological imaging modality. Single photon emission computerized tomography (SPECT) and positron emission tomography (PET) scans are the 2 commonest imaging modalities in medicine.   The report "  Global Nuclear Medicine Market, By Diagnostics (Single Photon Emission, Computed Tomography (SPECT), an...
Read more